Spots Global Cancer Trial Database for sts
Every month we try and update this database with for sts cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma | NCT00626704 | Locally Advance... Sarcoma Soft Tissue Sar... | AMG 655 Placebo Doxorubicin | 18 Years - | Amgen | |
| Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy | NCT05944913 | Soft Tissue Sar... | Prevena | 18 Years - | Centre Leon Berard | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Use of Propranolol Hydrochloride in the Treatment of Metastatic STS | NCT03108300 | Malignant Soft ... | Propranolol Hyd... Doxorubicin | 19 Years - | Ain Shams University | |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | NCT02549937 | Tumors | surufatinib | 18 Years - | Hutchmed | |
| Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | NCT02636725 | Alveolar Soft P... Soft Tissue Sar... | Axitinib Pembrolizumab | 16 Years - | University of Miami | |
| PP-Gemcitabine & External Beam Radiation-Sarcomas | NCT02046304 | Sarcoma | Gemcitabine Radiation Thera... | - | M.D. Anderson Cancer Center | |
| Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma | NCT00626704 | Locally Advance... Sarcoma Soft Tissue Sar... | AMG 655 Placebo Doxorubicin | 18 Years - | Amgen | |
| YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | NCT05448820 | Advanced Sarcom... Metastatic Sarc... Soft Tissue Sar... | YH001 Envafolimab Doxorubicin | 18 Years - | Tracon Pharmaceuticals Inc. | |
| PP-Gemcitabine & External Beam Radiation-Sarcomas | NCT02046304 | Sarcoma | Gemcitabine Radiation Thera... | - | M.D. Anderson Cancer Center | |
| Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy | NCT05944913 | Soft Tissue Sar... | Prevena | 18 Years - | Centre Leon Berard | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | NCT05813327 | Soft Tissue Sar... Sts Sarcoma,Soft Ti... | ADI PEG20 Ifosfamide Radiotherapy Mesna | 18 Years - | Washington University School of Medicine | |
| Exercise and Soft Tissue Sarcoma | NCT04921917 | Soft Tissue Sar... | neoadjuvant exe... | 18 Years - 85 Years | Duke University | |
| Exercise and Soft Tissue Sarcoma | NCT04921917 | Soft Tissue Sar... | neoadjuvant exe... | 18 Years - 85 Years | Duke University | |
| Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | NCT02636725 | Alveolar Soft P... Soft Tissue Sar... | Axitinib Pembrolizumab | 16 Years - | University of Miami | |
| Phase II Study of Doxorubicin and Avastin® in Sarcoma. | NCT00755261 | Sarcoma Soft Tissue Sar... | Avastin Doxorubicin | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
